Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigil Immunotherapy in Metastatic Ewing's Sarcoma
NCT02511132Phase 2Completed
- Sponsor
- Gradalis, Inc.
- Start
- Feb 2016
- Primary completion
- Nov 2018
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA), Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemogenovatucel-T in Ewing sarcoma (3 arms), sponsored by Gradalis, Inc. Primary endpoint: Number of Participants With Adverse Events Determined by Laboratory Assessments and Physical Examinations. Started Feb 2016; status: completed.
02
Drugs
gemogenovatucel-T
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT02511132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02511132.